Dr. Cheryl Blanchard's holdings primarily reside in Anika Therapeutics. Following her appointment as CEO in April 2020, her wealth was significantly tied to her position in the company, particularly in restricted stock units (RSUs) intended to reward her for long-term...

Dr. Cheryl Blanchard's holdings primarily reside in Anika Therapeutics. Following her appointment as CEO in April 2020, her wealth was significantly tied to her position in the company, particularly in restricted stock units (RSUs) intended to reward her for long-term performance. By 2020, Dr. Blanchard had vested stock worth about $303,640 from her previous roles. Notably, the equity she acquired consists of 73,726 shares in time-based restricted stock units that were granted based on her performance and loyalty to the company. This strategy aligns her financial success with the company’s growth, showing that as Anika's value increases, so does her overall wealth. The shares she accrued provide stability and a vested interest in Anika’s long-term future and innovation within the healthcare sector.